ACST:NSD-Acasti Pharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.71

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

1.31M

Average Target Price

USD 3.23 (+355.96%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD76.34B 51.29 38.52
REGN Regeneron Pharmaceuticals, Inc

N/A

USD63.70B 32.18 22.32
SGEN Seattle Genetics, Inc

N/A

USD30.18B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.03B 10.20 8.76
MRNA Moderna, Inc

N/A

USD23.24B N/A N/A
GMAB Genmab A/S

N/A

USD22.91B 49.21 4.63
BMRN BioMarin Pharmaceutical Inc

N/A

USD22.80B 201.29 120.75
INCY Incyte Corporation

N/A

USD22.77B 47.64 35.20
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD18.63B N/A N/A
BGNE BeiGene, Ltd

N/A

USD15.57B N/A N/A

ETFs Containing ACST

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -71.09% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.09% 2% F 2% F
Trailing 12 Months  
Capital Gain -50.11% 15% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.11% 15% F 12% F
Trailing 5 Years  
Capital Gain -78.53% 32% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.53% 31% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 4.36% 57% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.36% 56% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 83.74% 21% F 9% F
Risk Adjusted Return 5.20% 55% F 33% F
Market Capitalization 0.07B 22% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.12 44% F 26% F
Price / Cash Flow Ratio -2.87 32% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -212.26% 14% F 6% F
Return on Invested Capital -196.99% 8% F 3% F
Return on Assets -51.13% 19% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.15 91% A- 91% A-
Short Percent 0.42% 90% A- 86% B
Beta 1.11 71% C- 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector